In vivo effects of pardoprunox (SLV308), a partial D 2/D 3 receptor and 5-HT 1A receptor agonist, on rat dopamine and serotonin neuronal activity

Synapse

Volumn 65, Issue 10, 2011, Pages 1042-1051

  Bétry, Cécile ^a,b   Etiévant, Adeline ^a,b   Lambás Señas, Laura ^a,b   Mccreary, Andrew C ^c   Haddjeri, Nasser ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Dopamine; Dorsal raphe nucleus; Pardoprunox (SLV308); Parkinson's disease; Partial agonist; Serotonin; Ventral tegmental area

Indexed keywords

DOPAMINE; PARDOPRUNOX; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; DRUG EFFECT; DRUG MECHANISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE CELL; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM;

ANIMALS; BENZOXAZOLES; BRAIN; DOPAMINE; DOPAMINE AGONISTS; MALE; NEURONS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SYNAPTIC TRANSMISSION;

EID: 79960963438     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20936     Document Type: Article

References (57)

1. Adell A, Artigas F. 2004. The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems. Neurosci Biobehav Rev 28: 415-431.
2. Ahlenius S, Ericson E, Florvall L, Jimenez P, Hillegaart V, Wijkstrom A. 2000. In vivo characterization of novel full and partial 2-(4-aminophenyl)-N, N-dipropylethylamine dopamine D(2) receptor agonists. Eur J Pharmacol 394: 247-253.
3. Akunne HC, Zoski KT, Davis MD, Cooke LW, Meltzer LT, Whetzel SZ, Shih YH, Wustrow DJ, Wise LD, MacKenzie RG, Georgic LM, Heffner TG, Pugsley TA. 2000. PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects. Neuropharmacology 39: 1197-1210.
4. Baring MD, Walters JR, Eng N. 1980. Action of systemic apomorphine on dopamine cell firing after neostriatal kainic acid lesion. Brain Res 181: 214-218.
5. Barone P, Lamb J, Ellis A, Clarke Z. 2007. Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease. Mov Disord 22: 483-489.
6. Bennett JPJr, Piercey MF. 1999. Pramipexole-A new dopamine agonist for the treatment of Parkinson's disease. J Neurol Sci 163: 25-31.
7. Blandini F, Nappi G, Tassorelli C, Martignoni E. 2000. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 62: 63-88.
8. Boulay D, Depoortere R, Oblin A, Sanger DJ, Schoemaker H, Perrault G. 2000. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice. Eur J Pharmacol 391: 63-73.
9. Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL. 2004. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: Final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18: 733-746.
10. Bronzova J, Sampaio C, Hauser RA, Lang AE, Rascol O, Theeuwes A, van de Witte SV, van Scharrenburg G. 2010. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord 25: 730-738.
11. Bunney BS, Aghajanian GK. 1977. D-amphetamine-induced inhibition of central dopaminergic neurons: Direct effect or mediated by a striatonigral feedback pathway? Adv Biochem Psychopharmacol 16: 577-582.
12. Bunney BS, Aghajanian GK. 1978. D-amphetamine-induced depression of central dopamine neurons: Evidence for mediation by both autoreceptors and a striato-nigral feedback pathway. Naunyn Schmiedebergs Arch Pharmacol 304: 255-261.
13. Carta M, Carlsson T, Kirik D, Bjorklund A. 2007. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130: 1819-1833.
14. Cummings JL, Masterman DL. 1999. Depression in patients with Parkinson's disease. Int J Geriatric Psychiatry 14: 711-718.
15. Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N. 2009. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour. J Psychopharmacol 23: 177-189.
16. Etievant A, Betry C, Arnt J, Haddjeri N. 2009. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation. Neurosci Lett 460: 82-86.
17. Etminan M, Gill S, Samii A. 2003. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: A meta-analysis. Drug Safety 26: 439-444.
18. Floresco SB, West AR, Ash B, Moore H, Grace AA. 2003. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 6: 968-973.
19. Fox SH, Brotchie JM, Lang AE. 2008. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 7: 927-938.
20. Glennon JC, Van Scharrenburg G, Ronken E, Hesselink MB, Reinders JH, Van Der Neut M, Long SK, Feenstra RW, McCreary AC. 2006. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): A novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse 60: 599-608.
21. Gonon FG. 1988. Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24: 19-28.
22. Grace AA, Bunney BS. 1983. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons-1. Identification and characterization. Neuroscience 10: 301-315.
23. Gregoire L, Samadi P, Graham J, Bedard PJ, Bartoszyk GD, Di Paolo T. 2009. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord 15: 445-452.
24. Hadrava V, Blier P, Dennis T, Ortemann C, de Montigny C. 1995. Characterization of 5-hydroxytryptamine1A properties of flesinoxan: In vivo electrophysiology and hypothermia study. Neuropharmacology 34: 1311-1326.
25. Hagan JJ, Middlemiss DN, Sharpe PC, Poste GH. 1997. Parkinson's disease: Prospects for improved drug therapy. Trends Pharmacol Sci 18: 156-163.
26. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. 2002. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: A survey by the Canadian Movement Disorders Group. JAMA 287: 455-463.
27. Inzelberg R, Schechtman E, Nisipeanu P. 2003. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: An evidence-based comparison. Drugs Aging 20: 847-855.
28. Jankovic J. 1993. Natural course and limitations of levodopa therapy. Neurology 43: S14-S17.
29. Jenner P. 2002. Pharmacology of dopamine agonists in the treatment of Parkinson's disease. Neurology 58: S1-S8.
30. Jenner P. 2008. Functional models of Parkinson's disease: A valuable tool in the development of novel therapies. Ann Neurol 64(Suppl 2): S16-S29.
31. Johnston LC, Jackson MJ, Rose S, McCreary AC, Jenner P. 2010. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. Mov Disord 25: 2059-2066.
32. Joyce JN. 2001. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Therap 90: 231-259.
33. Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M. 2002. Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 54: 133-137.
34. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S. 1995. 7-(4-[4-(2, 3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3, 4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 274: 329-336.
35. Kreiss DS, Bergstrom DA, Gonzalez AM, Huang KX, Sibley DR, Walters JR. 1995. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol 277: 209-214.
36. Krosser S, Neugebauer R, Chassard D, Kovar A. 2007. Investigation of the impact of sarizotan on the pharmacokinetics of levodopa. Biopharmaceutic Drug Disposition 28: 339-347.
37. Lader M. 2008. Antiparkinsonian medication and pathological gambling. CNS Drugs 22: 407-416.
38. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA, Gonzalez AM, Sibley DR, Mailman RB. 1999. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20: 612-627.
39. Lledo A. 2000. Dopamine agonists: The treatment for Parkinson's disease in the XXI century? Parkinsonism Relat Disord 7: 51-58.
40. Lozano AM, Lang AE, Hutchison WD, Dostrovsky JO. 1998. New developments in understanding the etiology of Parkinson's disease and in its treatment. Curr Opin Neurobiol 8: 783-790.
41. Mailman RB, Murthy V. 2010. Third generation antipsychotic drugs: Partial agonism or receptor functional selectivity? Curr Pharm Des 16: 488-501.
42. McCall RB, Lookingland KJ, Bedard PJ, Huff RM. 2005. Sumanirole, a highly dopamine D2-selective receptor agonist: In vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. J Pharmacol Exp Therap 314: 1248-1256.
43. McCreary AC, Johnston L, Glennon J, Rose S, Jackson M, Jenner P, van Scharrenburg G. 2006. The in vivo characterization of SLV308: A novel dopamine D2/D3 partial agonist and 5-HT1A full agonist for the treatment of Parkinson's disease. Mov Disord 21: P92.
44. Mengod G, Villaro MT, Landwehrmeyer GB, Martinez-Mir MI, Niznik HB, Sunahara RK, Seeman P, O'Dowd BF, Probst A, Palacios JM. 1992. Visualization of dopamine D1, D2 and D3 receptor mRNAs in human and rat brain. Neurochem Int 20(Suppl): 33S-43S.
45. Mercuri NB, Saiardi A, Bonci A, Picetti R, Calabresi P, Bernardi G, Borrelli E. 1997. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. Neuroscience 79: 323-327.
46. Millan MJ, Gobert A, Newman-Tancredi A, Lejeune F, Cussac D, Rivet JM, Audinot V, Dubuffet T, Lavielle G. 2000. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218, 231 and L741, 626. J Pharmacol Exp Therap 293: 1048-1062.
47. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. 2002. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Therap 303: 791-804.
48. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates, 4th ed. New York: Academic Press. p 256.
49. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. 1996. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: Comparison to other dopamine receptor agonists. Eur J Pharmacol 312: 35-44.
50. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. 2000. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342: 1484-1491.
51. Smith Y, Kieval JZ. 2000. Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 23: S28-S33.
52. Temel Y, Boothman LJ, Blokland A, Magill PJ, Steinbusch HW, Visser-Vandewalle V, Sharp T. 2007. Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. Proc Naltl Acad Sci USA 104: 17087-17092.
53. Ungless MA, Magill PJ, Bolam JP. 2004. Uniform inhibition of dopamine neurons in the ventral tegmental area by aversive stimuli. Science 303: 2040-2042.
54. Urban JD, Vargas GA, von Zastrow M, Mailman RB. 2007. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32: 67-77.
55. Wang S, Zhang QJ, Liu J, Wu ZH, Wang T, Gui ZH, Chen L, Wang Y. 2009. Unilateral lesion of the nigrostriatal pathway induces an increase of neuronal firing of the midbrain raphe nuclei 5-HT neurons and a decrease of their response to 5-HT(1A) receptor stimulation in the rat. Neuroscience 159: 850-861.
56. White FJ, Wang RY. 1983. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054-1057.
57. Zesiewicz TA, Hauser RA. 2002. Depression in Parkinson's disease. Curr Psychiatry Rep 4: 69-73.